Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization

• Egile Nagusiak: Kanta Hori (Egilea), Shuhei Yamada (Egilea), Kenji Murata (Egilea), Haruka Miyata (Egilea), Yuka Mizue (Egilea), Aiko Murai (Egilea), Tomoyuki Minowa (Egilea), Kenta Sasaki (Egilea), Naoki Shijubou (Egilea), Terufumi Kubo (Egilea), Rena Morita (Egilea), Serina Tokita (Egilea), Takayuki Kanaseki (Egilea), Tomohide Tsukahara (Egilea), Takashige Abe (Egilea), Nobuo Shinohara (Egilea), Yoshihiko Hirohashi (Egilea), Toshihiko Torigoe (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Adoptive T cell therapy, using T cell receptor-engineered T (TCR-T) cells and chimeric antigen receptor T (CAR-T) cells, is a potent immunotherapy option. Bladder cancer is a prevalent urological malignancy, particularly in cases of muscle invasion and metastasis, for which systemic therapy is cruci...